Skip to main content
Premium Trial:

Request an Annual Quote

SpeeDx, Diagen Sign Distribution Agreement for Scandinavia

NEW YORK (GenomeWeb) – SpeeDx has announced a distribution agreement with Diagen, a Scandinavian clinical laboratory supplier.

The agreement will open crucial sales channels in Denmark, Sweden, and Norway for SpeeDx's PlexPCR and ResistancePlus real-time PCR product lines.

Using SpeeDx's technology, the PlexPCR range will enable Diagen customers to receive diagnostic information on STIs and other infectious diseases from a single test. The agreement will also provide Diagen customers access to SpeeDx's ResistancePlus MG assay, which tests for the Mycoplasma genitalium STI. SpeeDx's assay is the first CE-IVD test to simultaneously detect M. genitalium and genetic markers for azithromycin resistance, as recommended by new European guidelines on M. genitalium resistance screening in the management of  non-gonococcal urethritis.     

SpeeDx announced yesterday that the New South Wales Medical Devices Fund has granted the company A$2.5 million (US$2 million) for the continued rollout of the ResistancePlus MG test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.